Phase I trial shows bispecific ADC enhances tumor responses in ESCC patients, suggesting safety and effectiveness.
A phase I study of the bispecific antibody–drug conjugate BL-B01D1 shows encouraging safety and effectiveness. The drug, which targets EGFR and HER3, triggered side effects in most patients, but at the higher of two doses tested, it spurred tumor responses in almost 40% of patients.
No takes yet. Share an insight, caveat, or question.
Mitch Leslie (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: